Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio Growth (5y) (2014 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.30 Bn | 620.54 Bn | 17.26 Bn |
| 2 | AbbVie | 446.20 Bn | 439.63 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.25 Bn | 259.56 Bn | 11.24 Bn |
| 5 | Pfizer | 156.75 Bn | 145.05 Bn | 10.94 Bn |
| 6 | Sanofi | 52.12 Bn | 44.74 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.09 Bn | 43.09 Bn | - |
| 8 | Incyte | 24.61 Bn | 20.07 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.24 Bn | 18.58 Bn | 683.80 Mn |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54.53% |
| Mar 31, 2026 | 2.66% |
| Dec 31, 2025 | 15.86% |
| Sep 30, 2025 | -1.23% |
| Jun 30, 2025 | 72.51% |
| Mar 31, 2025 | 35.68% |
| Dec 31, 2024 | 15.32% |
| Sep 30, 2024 | -13.27% |
| Jun 30, 2024 | -8.39% |
| Mar 31, 2024 | -42.29% |
| Dec 31, 2023 | -3.05% |
| Sep 30, 2023 | -11.12% |
| Jun 30, 2023 | 24.33% |
| Mar 31, 2023 | -3.71% |
| Dec 31, 2022 | 19.97% |
| Sep 30, 2022 | 0.82% |
| Jun 30, 2022 | 142.03% |
| Mar 31, 2022 | -14.21% |
| Dec 31, 2021 | 8.82% |
| Sep 30, 2021 | -5.71% |